NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/05/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization735.25 mln
Float33.69 mln
Earnings Date08/12/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
2.18
Highly suspicious
1-Year Forecast
49.50
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-29.26
Deeply negative
Business Description
BioAge Labs is a clinical-stage pharmaceutical company focused on developing treatments for metabolic diseases by studying how aging affects the body at a molecular level. Its lead drug candidate, BGE-102, is currently in Phase 1 trials for cardiovascular disease, diabetic macular edema, and geographic atrophy, while the company also works on obesity treatments through its APJ agonist program. BioAge Labs works alongside Novartis to discover and confirm new drug targets linked to age-related diseases. Founded in 2015 and based in Emeryville, California, the company uses its proprietary human data platform to guide its research and development efforts.
